AlzeCure Pharma

AlzeCure Pharma is a Swedish biopharmaceutical company focused on developing small-molecule drug candidates for diseases of the central nervous system and pain. Its pipeline includes programs for Alzheimer’s disease, neuropathic pain, and other neurodegenerative or neurological indications, with development activities centered in Sweden.

— AlzeCure Pharma
%
Alzheimer’s disease programs40% Drug candidates and research programs targeting Alzheimer’s disease and related cognitive disorders.
Pain programs35% Programs focused on chronic and neuropathic pain, including TrkA-NAM and related assets.
Preclinical discovery platform20% Early-stage discovery work that generates new drug candidates and supporting scientific data.
Licensing and partnering5% Out-licensing and collaboration arrangements that monetize pipeline assets with partners.

AlzeCure does not sell mass-market products; its economic counterparties are primarily pharmaceutical and biotech...

  • Pharmaceutical licenseesprimary

    Buy rights to drug candidates or programs for further development and commercialization.

  • Biotech collaboration partnersprimary

    Co-develop specific assets, share development risk, and support clinical advancement.

  • Public grant and research funderssecondary

    Provide non-dilutive funding for clinical studies and scientific work.

  • Scientific and academic collaboratorssecondary

    Support preclinical and translational research that strengthens the pipeline.

AlzeCure’s operations are centered in Sweden, where the parent company conducts its business and where the group...

  • •Sweden is the operating base and reporting center
  • •R&D and corporate functions are run from Sweden
  • •Partnering opportunities are typically international
  • •Clinical and regulatory work can extend beyond Sweden
  • •No disclosed country revenue split is available

The company’s strategy is to advance a focused pipeline of CNS and pain assets through preclinical and clinical...

01
Advance lead clinical and preclinical assetsshort-term

Progressing candidates increases partnering value and de-risks the pipeline.

02
Strengthen partnering and licensing potentialmedium-term

The business model depends on external partners for downstream development and monetization.

03
Build scientific credibility and IP positionlong-term

Published data and patent protection improve negotiating leverage with larger pharma companies.

AlzeCure’s main risks are typical of a development-stage biotech company: clinical failure, dependence on key...

critical

Financing risk

Development-stage biotech typically requires repeated external capital before product revenues exist.

Scope
Ongoing R&D and clinical funding needs
Materiality
high
high

Clinical development risk

Drug candidates may fail to show efficacy or safety in human studies, which can end a program.

Scope
ACD856, ACD440, ACD137 and other pipeline assets
Materiality
high
high

Partnering and milestone risk

A large share of potential value in licensing deals is tied to future milestones and royalties that may never be achieved.

Scope
Future collaboration or license agreements
Materiality
high
high

Intellectual property risk

Patent expiry or weak protection can reduce partnering value and competitive exclusivity.

Scope
Drug candidates and platform technologies
Materiality
high
medium

Key-person risk

The company depends on specialized scientific, regulatory, and development expertise.

Scope
Management, research, and regulatory affairs teams
Materiality
medium
medium

Regulatory and trial approval risk

Clinical studies require regulatory permissions and compliance with trial standards.

Scope
Human clinical programs in Sweden and abroad
Materiality
medium
Going concern
Affects valuation of the company as a continuing development business
Lease accounting
Changes balance sheet leverage and operating expense presentation
Grant accounting
Can affect reported income timing and R&D expense offset
Milestone and collaboration accounting
Could create uneven revenue timing and contingent income
Development cost capitalization
Affects operating expenses and intangible asset recognition

Alpha Cognition Inc.

ACOG · Biological Products, (No Diagnostic Substances)

Alector, Inc.

ALEC · Biological Products, (No Diagnostic Substances)

CalciMedica, Inc.

CALC · Pharmaceutical Preparations

Aldeyra Therapeutics, Inc.

ALDX · Pharmaceutical Preparations

AYTU BIOPHARMA, INC

AYTU · Pharmaceutical Preparations

Ascelia Pharma

ACE.ST · Health Care

: 11/08/2026